Novel and Known Genetic Players in Hypertension: From Gene Expression to Striking Insights
Farzeen, A.; Berutti, R.; Pavlov, M.; Sharma, S.; Fuchs, M.; Lindemann, N.; Linkohr, B.; eQTLGen Consortium, ; von Scheidt, M.; Schunkert, H.; Peters, A.; Grallert, H.; Waldenberger, M.; Winkelmann, J.; Maegdefessel, L.; Teumer, A.; Prokisch, H.; Gieger, C.
Show abstract
Cardiovascular diseases (CVDs) are the most common non-communicable diseases, responsible for 17.9 million deaths each year. Hypertension is a major risk factor for CVDs. Gene expression data obtained from RNA sequencing can help identify novel genes associated with hypertension and provide deeper insights into the functional roles of the [~]2,000 known hypertension GWAS loci. In this study, we utilized RNA-seq data from 1,796 individuals from the KORA FF4 cohort. Differential gene expression analyses were done for hypertension and its phenotypes, i.e., systolic blood pressure, diastolic blood pressure and pulse pressure, followed by gene set enrichment analyses. The significant genes were then further tested in a sensitivity analysis using participants without any reported cardiometabolic disorders or medication use. To investigate the connection between genetic variants, environment and gene expression, we integrated RNA-seq data, genotyping array data and methylation data to perform eQTL and CpG methylation-gene expression analyses. Mendelian randomization analyses were performed to answer the question of causality between the gene expression of these genes and blood pressure phenotypes. Our findings highlight novel and known genetic contributors to hypertension, establish potential downstream consequences of hypertension-related genetic variants and CpG sites, and reveal that blood pressure is mostly a cause for change in gene expression. We propose 7 novel genes that can be further targeted as candidate genes for functional follow-ups to get insight into potential new pathways for hypertension, i.e., MIR23AHG (also known as LOC284454), PGPEP1, RNASEK-C17orf49, PDCD4-AS1, SNRPA1, AGO4 and CCT6P1. In light of Mendelian randomization analyses and what genes are druggable in our analyses, we recommend LMNA, already known to be involved in cardiovascular diseases, as a drug target for managing the adverse effects of hypertension. Our results provide a foundation for future functional studies and drug development efforts.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Identification of the molecular components of enhancer-mediated gene expression variation in multiple tissues regulating blood pressure 95%
- Essential hypertension is associated with changes in gut microbial metabolic pathways: A multi-site analysis of ambulatory blood pressure 95%
- Increased TRPV4 channel expression enhances and impairs blood vessel function in hypertension 94%
Similar papers in this journal
- A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood 95%
- Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption 94%
- Genetic correlates of vitamin D-binding protein and 25 hydroxyvitamin D in neonatal dried blood spots 94%
Similar papers in this journal
Similar papers in this journal
- Genome-wide association study of COVID-19 Breakthrough Infections and genetic overlap with other diseases: A study of the UK Biobank 94%
- A meta-analysis approach to gene regulatory network inference identifies key regulators of cardiovascular diseases 93%
- Identification of ATP2B4 regulatory element containing functional genetic variants associated with severe malaria 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.